Angiotensin II receptor blockade: Is there truly a benefit of adding an ACE inhibitor?

Hypertension

Volumn 41, Issue 1, 2003, Pages 31-36

  Forclaz, Andrei ^b   Maillard, Marc ^b   Nussberger, Jürg ^b   Brunner, Hans R ^b   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NONE

Author keywords

Angiotensin II; Angiotensin converting enzyme; Human; Losartan; Receptors, angiotensin; Telmisartan

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN ANTAGONIST; LISINOPRIL; LOSARTAN; TELMISARTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; NORMAL HUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VOLUNTEER;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; HUMANS; LOSARTAN; MALE; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; SINGLE-BLIND METHOD;

EID: 0037219665     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000047512.58862.A9     Document Type: Article

References (28)

1. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904-912.
2. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
4. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
5. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
6. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
7. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
8. Brunner HR, Menard J, Waeber B, Burnier M, Biollaz J, Nussberger J, Bellet M. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens. 1990;8:3-11.
9. Brunner HR, Waeber B, Nussberger J. Does pharmacological profiling of a new drug in normotensive volunteers provide a useful guideline to antihypertensive therapy? Hypertension. 1983;5(suppl III):III-101-III-107.
10. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4:966-972.
11. Nussberger J, Brunner DB, Waeber B, Brunner HR. True versus immunoreactive angiotensin II in human plasma. Hypertension. 1985;7(suppl I):I-1-I-7.
12. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N, Brunner HR. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Curdiovasc Pharmacol. 1990;15:276-282.
13. Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension. 1999;33:850-855.
14. Maillard MP, Wurzner G, Nussberger J, Centeno C, Burnier M, Brunner HR. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther. 2002;71:68-76.
15. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Ménard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted nonnotensives. Circulation. 1995;92:825-834.
16. Azizi M, Guyene TT, Chatellier G, Wargon M, Ménard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension. 1997;29:634-640.
17. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Maggon K, Shum L, Timmermans PBMW, Brunner HR. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation. 1991;83:1333-1342.
18. Maillard MP, Mazzolai L, Daven V, Centeno C, Nussberger J, Brunner HR, Bumier M. Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay. Am J Hypertens. 1999;12:1201-1208.
19. Nussberger J, Keller I, Waeber B, Brunner HR. Angiotensin II measurement with high-affinity monoclonal antibodies. J Hypertens Suppl. 1988;6:S424-S425.
20. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440-1444.
21. Hebert LA, Falkenhain ME, Nahman NS Jr, Cosio FG, O'Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol. 1999;19:1-6.
22. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 1999;33:851-856.
23. Waeber B, Brunner HR, Brunner DB, Curtet AL, Turini GA, Gavras H. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension. 1980;2:236-242.
24. Maillard MP, Rossat J, Nussberger J, Ramis J, Pontes C, Burnier M, Brunner HR. Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. J Cardiovasc Pharmacol. 2000;35:383-389.
25. Stangier J, Su CA, van Heiningen PN, Meinicke T, van Lier JJ, de Bruin H, Tamminga WJ, Jonkman JH. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol. 2001;38:672-685.
26. Ferguson RK, Turini GA, Brunner HR, Gavras H, McKinstry DN. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet. 1977;1:775-778.
27. Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther. 1998;15:206-217.
28. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.